Post-marketing surveillance for acute Kawasaki Disease under Remicade treatment

Post-marketing surveillance for acute Kawasaki Disease under Remicade treatment - SAKURA study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000025429

Enrollment

140

Registered

2016-12-27

Start date

2016-03-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Kawasaki disease

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with acute Kawasaki disease who receive the Drug (Limited to those having inadequate response to conventional therapy)

Exclusion criteria

Exclusion criteria: Patients with acute Kawasaki disease who meet "CONTRAINDICATIONS" to the use of the Drug

Design outcomes

Primary

Measure	Time frame
Defervescence rate within dosage 48 hours Incidence of advers drug reactions	—

Secondary

Measure	Time frame
Change in defervescence rate Duration of fever Incidence of the coronary lesion Overall improvement Infections caused by administration of live vaccines	—

Countries

Japan

Contacts

Public ContactItsuro Umebayashi

Tanabe Pharma Corporation Pharmacovigilance Department

tp-pms-shinchoku.JP@ml.tanabe-pharma.com06-6205-5223

Outcome results